StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences in-process research and development (IPR&D) impairment charges ($M) ($M)

Form 10-Q / 10-K Consolidated Statements of Operations

Latest, FY2025
1,024
Period ended Dec 31, 2025
Change on a year earlier
-78.0%
4,663 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIn-process research and development (IPR&D) impairment charges ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,024-78.0%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 20244,663+303.7%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 20231,155+22.4%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 2022944+0.5%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 2021939–Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 20200-100.0%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 2019800-2.4%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 2018820–Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 20170-100.0%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 2016432–Form 10-K (filed 2019-02-26) ↗
FY2015Dec 31, 20150–Form 10-K (filed 2018-02-27) ↗
FY2014Dec 31, 20140–Form 10-K (filed 2017-02-27) ↗

Cite this data

StockData. (2026). Gilead Sciences In-process research and development (IPR&D) impairment charges ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/iprd_impairment_exp

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.